# EDGAR Filing Document

**Accession Number:** 0001322505
**File Stem:** 0001193125-23-004149
**Filing Date:** 2023-1
**Character Count:** 7503
**Document Hash:** 98e34db46a5208c3537957fc7bd2f833
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-004149.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001193125-23-004149

**CONFORMED SUBMISSION TYPE**: SC TO-C

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALBIREO PHARMA, INC.
- **CENTRAL INDEX KEY:** 0001322505
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-83386
- **FILM NUMBER:** 23516575

**BUSINESS ADDRESS:**
- **STREET 1:** 10 POST OFFICE SQUARE
- **STREET 2:** SUITE 502 SOUTH
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
- **BUSINESS PHONE:** 857-415-4774

**MAIL ADDRESS:**
- **STREET 1:** 10 POST OFFICE SQUARE
- **STREET 2:** SUITE 502 SOUTH
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biodel Inc
- **DATE OF NAME CHANGE:** 20050331
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ipsen, S.A.
- **CENTRAL INDEX KEY:** 0001370483
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C

**BUSINESS ADDRESS:**
- **STREET 1:** 42, RUE DU DOCTEUR BLANCHE
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75016
- **BUSINESS PHONE:** 011 33144961010

**MAIL ADDRESS:**
- **STREET 1:** 42, RUE DU DOCTEUR BLANCHE
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75016

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**SCHEDULE TO** 

**TENDER OFFER STATEMENT UNDER SECTION 14(D)(1)** 

**OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934** 

------

## ALBIREO PHARMA, INC.
**(Name of Subject Company (Issuer))** 

**ANEMONE ACQUISITION CORP.** 

**(Offeror)** 

**a wholly owned subsidiary of** 

**IPSEN BIOPHARMACEUTICALS, INC.** 

**(Offeror)** 

**a wholly owned subsidiary of** 

**IPSEN PHARMA SAS** 

**(Offeror)** 

**a wholly owned subsidiary of** 

**IPSEN S.A.** 

**(Offeror)** 

**(Names of Filing Persons (identifying status as offeror, issuer or other person))** 

**Common Stock, Par Value $0.01 Per Share** 

**(Title of Class of Securities)** 

**01345P106** 

**(CUSIP Number of Class of Securities)** 

**Francois Garnier, EVP, General Counsel and Chief Business Officer** 

**Ipsen Pharma SAS** 

**65 Quai Georges Gorse** 

**92100 Boulogne-Billancourt, France** 

**Tel. +33 1 58 33 50 00** 

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)** 

***Copies to:***

---

| | |
|:---|:---|
| **Tony Chan, Esq.**<br> **Orrick, Herrington & Sutcliffe LLP**<br> **Columbia Center**<br> **1152 15th Street, N.W.**<br> **Washington, DC 20005-1706** | **Niki Fang, Esq.**<br> **Orrick, Herrington & Sutcliffe LLP**<br> **The Orrick Building**<br> **405 Howard Street**<br> **San Francisco, CA 94105-2669** |

---

------

**CALCULATION OF FILING FEE** 

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**Transaction Valuation\*** | **Amount of Filing Fee\*** |
| &nbsp;&nbsp;&nbsp;Not applicable\* | Not applicable\* |

---

\* A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ third-party tender offer subject to Rule 14d-1.

☐ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3.

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 13d-1(d) (Cross-Border Third-Party Tender Offer)

------

The pre-commencement communication filed under cover of this Schedule TO relates to a planned tender offer (the "Offer") by Anemone Acquisition Corp., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), for all of the issued and outstanding shares of common stock, par value $0.01 per share (the "Common Stock"), of Albireo Pharma, Inc. (the "Company"), pursuant to an Agreement and Plan of Merger, dated as of January 8, 2023 (the "Merger Agreement"), by and among the Company, Parent, Purchaser and Ipsen Pharma SAS, a French société par actions simplifiée, as Guarantor for certain purposes under the Merger Agreement ("Guarantor"). Guarantor is a wholly owned subsidiary of Ipsen S.A., a French société anonyme.

The Offer for the outstanding shares of Common Stock has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities. The solicitation and offer to buy shares of Common Stock will only be made pursuant to the tender offer materials that Ipsen, Parent, Purchaser and Guarantor intend to file with the U.S. Securities and Exchange Commission (the "SEC") upon commencement of the Offer. At the time the Offer is commenced, Ipsen, Parent, Purchaser and Guarantor will file a tender offer statement on Schedule TO with the SEC, and the Company will file a solicitation/recommendation statement on Schedule 14D-9 ("Solicitation/Recommendation Statement") with the SEC with respect to the Offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. THE COMPANY'S STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF THE COMPANY'S SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. Both the tender offer statement and the Solicitation/Recommendation Statement will be mailed to the Company's stockholders free of charge. Once filed with the SEC, Company stockholders will be able to obtain a free copy of these materials and other documents with respect to the Offer at the website maintained by the SEC at www.sec.gov. The tender offer materials may also be obtained (when available) free of charge on the Company's internet website at www.albireopharma.com, by contacting the Company's Investor Relations Department at (857) 254-5555 or by contacting the information agent for the tender offer who will be named in the tender offer materials.

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [Joint Press Release dated January 9, 2023 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K of Albireo, Inc. filed with the SEC on January 9, 2023 (File no. 001-33451)).](http://www.sec.gov/Archives/edgar/data/1322505/000110465923001979/tm232666d1_ex99-1.htm) |

---